4.8· 4 reviewsout of 5In stock
Thymosin Alpha-1 10mg vials, a 28-amino-acid acetylated peptide. Third-party tested for purity, peptide content and endotoxins with the COA published.
Thymosin Alpha‐1 (TA‐1) Immune Research Overview
Thymosin Alpha‐1 (TA‐1) is a high‐purity, research-grade 28‐amino acid peptide originally isolated from thymic tissue and now synthesized as thymalfasin, a defined tool for studying T‐cell biology, host defense, and immune modulation. It has been widely investigated in models of infection, cancer, vaccine response, and immune dysregulation.
Molecular Composition and Mechanistic Profile
Thymosin Alpha‐1 (TA‐1 / Thymalfasin): A synthetic form of the naturally occurring thymic peptide that functions as a protein messenger in adaptive immunity.
Mechanistically, Thymosin A‐1:
Enhances maturation, differentiation, and function of T lymphocytes (thymocytes and peripheral T cells), including cytotoxic T cells and helper subsets.
Activates dendritic cells and natural killer (NK) cells, boosts antigen presentation, and modulates cytokine and chemokine production (e.g., interferons, interleukins) to coordinate innate and adaptive responses.
May increase expression of MHC class I molecules, improve macrophage efficiency, and influence thrombin activity, giving it a broad footprint in immune surveillance, inflammation, and hemostasis.
These properties make TA‐1 a versatile model for probing how the immune system responds to infection, tumor antigens, and vaccine stimuli.
Integrated Research Applications
Thymosin Alpha‐1 is used across a wide spectrum of immunology and translational research. Key domains include:
Infectious disease models (viral, bacterial, and fungal), including hepatitis, respiratory infections, tuberculosis, and opportunistic infections, where TA‐1 is used to explore enhanced pathogen clearance and immune resilience.
Oncology and tumor immunology, focusing on T‐cell–mediated tumor recognition, checkpoint interactions, and combination strategies with chemotherapy, radiotherapy, or other immunomodulators.
Vaccine adjuvant studies, where TA‐1 is evaluated for its capacity to improve antigen-specific responses, antibody titers, and memory‐cell formation.
Chronic immune dysfunction and inflammatory conditions, including immune exhaustion, chronic fatigue, autoimmune settings, and gut–immune axis research.
These models use TA‐1 to interrogate how restoring or amplifying cell‐mediated immunity affects disease progression and recovery.
Analytical Validation, Formulation, and Care
Research suppliers provide Thymosin Alpha‐1 as a lyophilized powder at defined content per vial (e.g., 5 mg or 10 mg), designed for reconstitution immediately prior to experimental use. Typical quality features are:
Purity ≥98–99% confirmed by high-performance liquid chromatography (HPLC).
Identity verified via mass spectrometry and sequence analysis to match the
native TA‐1 sequence.
Pharmaceutical‐grade manufacturing standards and batch documentation,
supporting consistent performance across experiments.
Product care guidance from vendors includes: storing vials in a cool, dry place away from light, reconstituting under sterile conditions, refrigerating constituted solutions, and freezing at around −20 °C for longer-term storage to maintain integrity.
NextGenPeps supplies Thymosin Alpha-1 as a high-purity research peptide intended solely for laboratory investigation. This compound is not approved for human use and is not marketed for therapeutic, diagnostic, or dietary purposes.
99.58%
HPLC purity · Tested by Bioviridian
Thymosin Alpha-1 is supplied in the product format and quantity shown for the selected variant. Please inspect the sealed package when it arrives and contact support promptly if the package or labeling appears damaged.
Orders are shipped within the United States via USPS. Transit times are typically 3–7 business days, depending on destination and carrier conditions. Tracking information is provided when available.
Storage requirements are product-specific. Keep Thymosin Alpha-1 in its original labeled container and follow the product documentation or manufacturer instructions supplied with the order. Contact support if the applicable storage guidance is not available.
Due to the nature of research materials, NextGenPeps orders are final and are not eligible for refunds, returns, or exchanges. Review the shipping and reship policies before ordering.
No. NextGenPeps materials are supplied strictly for laboratory research and development use and are not intended for human or animal consumption, clinical use, diagnostic use, cosmetic use, or dietary use.
TA‐1 enhances cell‐mediated immunity by promoting T‐cell maturation and function, activating dendritic cells and NK cells, and modulating cytokine and chemokine production, thereby strengthening antiviral, antibacterial, and antitumor responses. Because it acts at multiple checkpoints in both innate and adaptive immunity—T cells, NK cells, dendritic cells, cytokines, and antigen presentation—TA‐1 allows researchers to model complex host‐defense scenarios, vaccine adjuvant effects, and immune restoration in immunocompromised or chronically infected settings.
Thymosin Alpha 1 is a 28 amino acid synthetic peptide originally isolated from thymic tissue that serves as a key subject in immunology research due to its role as an immunomodulatory compound. First characterized in the 1970s, it mimics a naturally occurring thymic hormone involved in T-cell development and immune regulation pathways. In laboratory studies, researchers use it to investigate thymic peptides, Toll-like receptor signaling, and cytokine production in immune cell cultures. Its acetylated N-terminus contributes to stability, making it suitable for various biochemical assays exploring adaptive and innate immunity mechanisms. Scientific literature frequently examines Thymosin Alpha 1 in models of viral infections, cancer immunotherapy, and vaccine adjuvants to better understand immune enhancement strategies.
Thymosin Alpha 1 acts as an immunomodulator that promotes maturation and differentiation of T-cells while activating dendritic cells and natural killer cells through Toll-like receptor pathways such as TLR2, TLR7, and TLR9. Studies show it stimulates production of cytokines including interferon-gamma, interleukin-2, and interleukin-10, helping balance Th1/Th2 immune responses in experimental models. Researchers observe its ability to enhance antigen presentation, support antibody responses, and regulate inflammation in preclinical infection and tumor studies. It also demonstrates anti-apoptotic effects on lymphocytes and potential antitumor activities via pathways like PTEN-mediated apoptosis.
Thymosin Alpha-1 is supplied as a lyophilized white powder that researchers store in sealed vials at -20°C for long-term stability, often extending shelf life up to 12 months or more when kept frozen and protected from moisture. Short-term storage at 2-8°C in a refrigerator is acceptable for periods up to several months without significant degradation according to supplier guidelines. Once reconstituted with bacteriostatic water or sterile saline for experimental use, the solution should be kept refrigerated at 2-8°C and typically utilized within 7 to 30 days depending on the specific protocol and concentration. Proper handling requires minimizing exposure to light, avoiding repeated freeze-thaw cycles, and maintaining aseptic conditions to prevent contamination in laboratory settings.
✓ 99.81% purity
✓ 99.310% purity
✓ 99.72% purity
✓ 99.76% purity
✓ 99.78% purity
